Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lanreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 known ✓ | P35346 | 16/20 | 1.00 |
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 1.00 |
| ▸ | SSTR3 | P32745 | 9/20 | 1.00 |
| ▸ | SSTR1 | P30872 | 3/20 | 1.00 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanreotide SCHEMBL19472556 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29381700 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29356077 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14802383 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19962799 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14674691 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29450601 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL21091289 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL22928940 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL28187023 | 0.99 | SSTR5 (0.99) | SSTR5SSTR2SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215527-A2 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |
| EP-4618991-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Novartis AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| EP-3684794-B1 | SOMATOSTATIN PRODRUGS | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIV OF JERUSALEM LTD (IL) | 2025-08-06 | — | — | EP | disclosed |
| US-20240197715-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-20240165282-A1 | CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF | STARGET PHARMA LTD. (IL) | 2024-05-23 | — | — | US | disclosed |
| WO-2024105610-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| EP-4301392-A1 | CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF | Starget Pharma Ltd. (IL) | 2024-01-10 | — | — | EP | disclosed |
| CN-115397809-A | Macrocyclic pantetheine derivatives and uses thereof | 彗星医疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2022185315-A1 | CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF | STARGET PHARMA LTD. (IL) | 2022-09-09 | — | — | WO | disclosed |
| US-20220242947-A1 | PROVASOPRESSIN ANTAGONISTS AND USES THEREOF | WOOMERA THERAPEUTICS | 2022-08-04 | — | — | US | disclosed |
| US-20220088150-A1 | Octreotide Microsphere-Based Arterial Embolization for Treating Obesity | BIOVENA SCIENCE LLC (US) | 2022-03-24 | — | — | US | disclosed |
| US-11261215-B2 | Somatostatin prodrugs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-01 | — | — | US | disclosed |
| CN-114057886-A | Somaltulipide derivative and preparation method thereof | 宁波鲲鹏生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197715-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | WRN, RECQL, BLM | SSTR5 2940/4885SSTR2 3377/4885SSTR3 3672/4885 |
| US-11261215-B2 | Somatostatin prodrugs | VIP, SSTR4, SSTR5 | SSTR5 3/4885SSTR2 6/4885SSTR3 4/4885 |
| US-20240165282-A1 | CONFORMATIONAL CONSTRAINED SOMATOSTATIN RECEPTOR 3 PEPTIDE LIGANDS AND THEIR CONJUGATES AND USES THEREOF | SSTR3, SSTR4, SSTR5 | SSTR5 3/4885SSTR2 5/4885SSTR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.